Table 1 of
Hill, Mol Vis 2018; 24:712-726. Table 1 of
Hill, Mol Vis 2018; 24:712-726.
Table 1. Experimental design.
| Number of rats | Treatment group (n=number of eyes/group) | Measured endpoints |
|---|---|---|
| 12 rats | IV Vehicle (n=4) 5 ul IV siEGFP (20ng; n=4) 5 ul IV siRhoA (10ng; n=4) 5 ul IV siEGFP (15ng; n=4) 5 ul IV siRhoA (20ng; n=4) 5 ul IV siRhoA (30ng; n=4) 5 ul IV siRhoA (40ng; n=4) | RT–PCR (to assess knockdown efficiency and the activation of innate immunity) |
| 3 Rats | Intact control eyes (n=3) | IHC (contractility & fibrosis) |
| 4 Rats | 3.5 ul IC of 5ng/µl TGFβ1 (n=4) | 7d IHC (contractility & fibrosis) |
| 3.5 ul IC 3.5ul PBS (n=4) | 7d IHC (contractility & fibrosis) | |
| 4 Rats | 3.5 ul IC 5ng/µl TGFβ1 (n=4) | 35d IHC (contractility & fibrosis) |
| 3.5 ul IC PBS (n=4) | 35d IOP; IHC (contractility & fibrosis) | |
| 6 Rats | 3.5 ul IC 5ng/µl TGFβ1+5ng/µl siRhoA (n=6) | 7d IOP; IHC (contractility & fibrosis) |
| IC 5 ng/µl TGFβ1+5ng/µl siEGFP (n=6) | 7d IOP; IHC (contractility & fibrosis) | |
| 6 Rats | IC 5 ng/µl TGFβ1+5ng/µl siRhoA (n=6) | 35d IOP; IHC (contractility & fibrosis) |
| IC 5 ng/µl TGFβ1+5ng/µl siEGFP (n=6) | 35d IOP; IHC (contractility & fibrosis) |